BioSpace News Archive

Aquestive Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today announced the underwriters of its previously announced initial public offering of common stock have partially exercised their over-allotment option to purchase additional shares.

Neurocrine Biosciences, Inc.(NASDAQ: NBIX) today announced it will present data from its movement disorders programs, including additional long-term results for INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and data analyses from a Phase III study on opicapone, an investigational treatment for Parkinson’s disease.

Zomedica Pharmaceuticals Corp. announced that all ordinary and special resolutions were passed at the Annual and Special Meeting of Shareholders, which was held today in Toronto, Ontario, Canada.

Kewaunee Scientific Corporation announced that the Company plans to release its first quarter fiscal year 2019 financial results on Tuesday, August 28, 2018 after the close of trading.

Illumina, Inc. announced its intention to offer, subject to market and other conditions, approximately $650 million aggregate principal amount of convertible senior notes due 2023

Neptune Technologies & Bioressources Inc. announces the voting results for the matters listed in its management proxy circular dated July 17, 2018 held at its Annual and Special Meeting of Shareholders in Montreal, Canada on August 15, 2018 (the “AGM”).

The 4th annual Aspiration Summit, a special 4-day event for young adults with Autism Spectrum Disorder and related profiles, will be held September 5-9 in Jackson Hole, Wyoming.

Medpace Holdings, Inc. announced that it will present at the following investor conference in September:

Marathon Kids announced the official opening of their Marathon Kids national grant for the 2018-2019 school year.

Primetime Life Sciences, LLC, a pharmaceutical company focused on discovery and development of new and smart treatments by using a multi-disciplinary, highly collaborative “bench-to-bedside” approach, today announced it has been awarded a Fast-Track Small Business Innovation Research (SBIR) grant by the National Institute of Health for development of depression.